Rosenberg M, et al. - Researchers tested a Drug Coated Balloon-only strategy (DCB-only) in patients with coronary lesions in this prospective, observational all-comers registry. Patients with de-novo coronary artery disease (CAD) were mainly included in this study conducted as an international, multicenter registry. However, the inclusion of patients with in-stent restenosis (ISR) was also possible. The focus was on the rate of clinically driven target lesion revascularization (TLR) after 9 months. Participants included 1,025 patients with a mean age of 64.0 ± 11.2 years. They noted that the majority of treated lesions were de-novo (66.9%), followed by drug-eluting-stent ISR (DES-ISR; 22.6%) and bare-metal-stent ISR (BMS-ISR; 10.5%). Higher TLR rates were noted in subgroup analyses in relation to lesion type and additional stent implantation. Overall, low major adverse cardiac event (MACE) and TLR rates were observed in association with DCB-only angioplasty of de-novo coronary lesions, suggesting the utility of DCBs as an attractive alternative for the interventional, stentless treatment of suitable de-novo coronary lesions.